News

Study reveals how patients’ smoking history changes evolution of lung cancer

Posted: 27 April 2023 Understanding the differences in the evolution of lung cancer between smokers and non-smokers could be the key to unlocking new treatments. Researchers evaluated lung cancer progression in smokers, compared with people who had never smoked, and…

Landmark Malawi trial boosts iron levels in pregnant women

Posted: 27 April 2023 The World Health Organization (WHO) currently recommends oral iron taken twice daily as the standard of care in developing nations, but adherence to this treatment is poor. The finding, driven by a collaboration between…

HER2-targeted DEP SN-38 ADC outperforms in HER2+ human cancer model

Posted: 26 April 2023 Starpharma today announces that it has developed a HER2-targeted DEP® SN-38 antibody-drug conjugate (ADC), which has shown significant anti-tumour activity in a HER2+ human ovarian cancer xenograft model, outperforming the approved ADC product, Enhertu®[2]. ADCs…

AZD0466 active in small cell lung cancer patient models

Posted: 21 April 2023 Starpharma announces AZD0466 results from a preclinical study in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models. Starpharma’s partner, AstraZeneca, presented these results overnight at the American Association for Cancer Research (AACR) Annual Meeting.…

International partnership launches Monash University-Helmholtz lab to solve global oncology, cardiology and infectious disease challenges

Posted: 21 April 2023 Monash University has partnered with the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), a member of the Helmholtz Association of German Research Centres to establish the Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics (MHELTHERA) to enable clinical translation at a launch…

ANDHealth Partners with Chicago ARC to Bring Australian Digital Health Startups into the U.S. Market

Posted: 21 April 2023 Chicago ARC Executive Director Kate Merton and ANDHealth CEO and Managing Director Bronwyn Le Grice today announced an exciting new partnership to connect Australia’s best and brightest digital health companies with U.S. partners and…

BioMelbourne Network thanks Professor Brendan Murphy

Posted: 19 April 2023 BioMelbourne Network thanks Professor Brendan Murphy AC for his outstanding contributions to health and public health in various roles, including Secretary of the Australian Government Department of Health and Aged Care.  “As Chief Medical…

DAYBUE (trofinetide) launched in US – Neuren earns US$40m

Posted: 19 April 2023 Neuren Pharmaceuticals reported that its North America partner Acadia Pharmaceuticals (NASDAQ: ACAD) has announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of…

DEP cabazitaxel Phase 2 clinical trial completes enrolment and treatment

Posted: 19 April 2023 Starpharma announces that it has completed enrolment and treatment of patients for the Phase 2 clinical trial of its investigational anticancer product DEP cabazitaxel. Encouraging efficacy signals, including significant tumour shrinkage and substantial tumour…

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

Posted: 19 April 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of an open-label Phase II trial evaluating eftilagimod…

First Patient Recruited to Cohort 3 of ACCENT Trial in Pancreatic Cancer

Posted: 19 April 2023 Amplia Therapeutics Limited is pleased to advise that dosing of the first patient in Cohort 3 of the Company’s ongoing Phase 1b/2a ACCENT clinical trial of FAK inhibitor AMP945 in pancreatic cancer has begun.…

Two New Deoxymab Patents Granted in the USA

Posted: 19 April 2023 Patrys Limited, a therapeutic antibody development company, is pleased to announce that the US Patent and Trademark Organisation has granted two patents that provide further intellectual property protection for Patrys’ deoxymab antibody technology until…

Home

News & opinion

Member Directory

Events